Perth stroke treatment hits phase 2
A Perth based biotechnology company is preparing to enter the Phase 2 ‘proof of concept’ clinical trial of its ground-breaking neuroprotective drug ARG-007, for acute ischaemic stroke (AIS) patients. Read More...